Birchview Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Birchview Capital’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,000	Closed	-$1.16M	–	75
2025 Q3	$1.16M	Hold	30,000	–	–	0.88%	32
2025 Q2	$830K	Sell	30,000 -6	-0%	-$153	0.82%	28
2025 Q1	$666K	Buy	30,006 +6	+0%	+$123	0.58%	28
2024 Q4	$593K	Hold	30,000	–	–	0.48%	28
2024 Q3	$750K	Hold	30,000	–	–	0.65%	25
2024 Q2	$560K	Hold	30,000	–	–	0.52%	28
2024 Q1	$592K	Hold	30,000	–	–	0.48%	33
2023 Q4	$526K	Hold	30,000	–	–	0.41%	33
2023 Q3	$521K	Hold	30,000	–	–	0.44%	34
2023 Q2	$422K	Hold	30,000	–	–	0.32%	37
2023 Q1	$323K	Hold	30,000	–	–	0.25%	41
2022 Q4	$449K	Hold	30,000	–	–	0.32%	36
2022 Q3	$385K	Hold	30,000	–	–	0.27%	44
2022 Q2	$291K	Hold	30,000	–	–	0.21%	48
2022 Q1	$298K	Hold	30,000	–	–	0.21%	52
2021 Q4	$353K	Hold	30,000	–	–	0.23%	52
2021 Q3	$342K	Buy	30,000 +10,000	+50%	+$130K	0.23%	51
2021 Q2	$279K	Buy	+20,000	New	+$304K	0.17%	56

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Birchview Capital's KNSA Position: Q4 2025 in Review

Birchview Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 30,000 shares — an estimated $1.16M sold.

Birchview Capital first reported a position in KNSA in Q2 2021 and held it in 18 quarters. The position peaked at $1.16M in Q3 2025. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

Birchview Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Birchview Capital sold 30,000 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $1.16M.
Birchview Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
Birchview Capital's Kiniksa Pharmaceuticals position peaked at $1.16M in Q3 2025.
224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.